- Decision of 22/05/2023 defining the form, content and procedures for the reporting of adverse events and new developments in the field of research mentioned in research mentioned in 1° of Article L. 1121-1 of the French public health code concerning medicinal products for human use.
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 5 – 8 June 2023
